Silence Therapeutics' Divesiran Hits Phase 2 Endpoints in Polycythemia Vera Trial
Event summary
- Silence Therapeutics' Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) met primary and secondary endpoints, with 88% response rate vs. 19% for placebo.
- Both dosing regimens (Q6W and Q12W) showed strong efficacy, reducing phlebotomy rates significantly compared to placebo.
- Divesiran was well-tolerated with no new safety findings observed.
- Company plans to present full results at an upcoming medical congress and initiate Phase 3 development.
The big picture
Silence Therapeutics' positive Phase 2 results for divesiran highlight the potential of siRNA therapies in treating polycythemia vera, a rare blood cancer with significant unmet medical needs. The trial's success positions Silence to compete in a niche market where current treatments are limited to phlebotomies and non-specific cytoreductive agents. The company's ability to advance divesiran through Phase 3 and secure regulatory approval will be critical in determining its long-term strategic value.
What we're watching
- Regulatory Pathway
- Whether the FDA Fast Track and Orphan Drug designations will accelerate divesiran's approval process.
- Market Differentiation
- How Silence Therapeutics positions divesiran as a best-in-class treatment in a space with limited approved therapies.
- Execution Risk
- The pace at which Silence can initiate and complete Phase 3 trials to bring divesiran to market.
Related topics